Abstract: The present invention provides a new compositions and methods to enable the safe administration of pyridostigmine to mammalian subjects, including those with myasthenic syndromes including Myasthenia Gravis, with said compositions comprising combinations, including fixed-dose combinations, of an antagonist of the 5-hydroxytryptamine subtype-3 receptor (“5HT3-antagonist”) with an effective dose of pyridostigmine. The compositions and methods of the present invention provide for an increase in the tolerable dose of pyridostigmine over that of pyridostigmine when administered alone.

Abstract: There is provided a convenient new treatment of Parkinson disease by a frequent administration of optimal levodopa doses mimicking a continuous intravenous or infusion treatment, thus mitigating motor complications; and a new carbidopa/levodopa pharmaceutical unit form providing said new treatment.

Abstract: The present invention proposes an improvement of the efficacy of donepezil for the palliative treatment of Dementia of the Alzheimer-type by counteracting its peripheral dose-limiting adverse effects with a selective peripheral M1-antagonist such as, preferably, pirenzepine, thus enabling a safe increase of the donepezil dose and consequently improved efficacy. In particular, an aim of the present invention is at least the slowing of the progression of dementia in patients suffering from a Hypocholinergic Disorder such as Alzheimer disease, Lewy body disease, Parkinson's Disease or Mild Cognitive Impairment by a safe administration of donepezil increased doses in combination with pirenzepine, as a peripheral antimuscarinic agent. This combination allows said safe treatment where other donepezil combinations failed.

Abstract: The present invention describes the combination of a NK1-antagonist with pramipexole or a pharmaceutically acceptable salt or solvate thereof, useful for treating depressive disorders, including major depressive disorder.

Abstract: The present invention describes the combination of a NK1-antagonist with pramipexole or a pharmaceutically acceptable salt or solvate thereof, useful for treating depressive disorders, including major depressive disorder.

Abstract: An assay for using signaling kinases alone or in combination with oligomeric forms of neurodegenerative proteins can include: a) providing a biological sample, e.g., a blood sample, from a subject; b) enriching for neuronally (e.g., central nervous system (“CNS”)) derived microparticles, e.g., exosomes, from the blood sample; c) removing proteins from the surface of the isolated exosomes to produce scrubbed exosomes; d) determining, in the isolated internal contents, set of biomarkers including: (1) at least one signaling kinase and, optionally, at least one oligomeric form of a neurodegenerative protein; or (2) a plurality of different signaling kinases.

Abstract: The present invention describes the use of a NK1-antagonist, in constant combination with pyridostigmine, to facilitate the treatment of a patient suffering from myasthenia gravis by providing a therapeutically effective pyridostigmine bromide daily dose without the dose-limiting gastro-intestinal adverse effects.

Abstract: There is provided a convenient new treatment of Parkinson disease by a frequent administration of optimal levodopa doses mimicking a continuous intravenous or infusion treatment, thus mitigating motor complications; and a new carbidopa/levodopa pharmaceutical unit form providing said new treatment.

Abstract: The present invention describes the use of a 5HT3-antagonist, in combination with a 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine, to reduce adverse effects and to facilitate the neuroprotective treatment of a patient suffering from a synucleinopathic disorder to enable a therapeutically effective 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine daily dose without the dose-limiting adverse effects caused by pramipexole when administered alone.

Abstract: The present invention relates to compositions comprising an antiemetic, particularly including 5-HT3 antagonist and/or NK-1 antagonist antiemetics, in combination with a choline esterase inhibitor such as an acetylcholine esterase inhibitor and/or a butyrylcholine esterase inhibitor, and methods of using the composition to provide improved protection of subjects at risk of organophosphorus poisoning, or, for the treatment, prevention, or alleviation/reduction of toxicity from an organophosphorus compound, by enabling the use of a highly protective daily dose of the choline esterase inhibitor without the typical adverse effects.

Abstract: The present invention describes the administration of an NK1 antagonist, in combination with neostigmine methylsulfate, intravenously, via subcutaneous infusion, or both intravenously and via subcutaneous infusion to facilitate the treatment of a patient suffering from myasthenia gravis by providing a therapeutically effective neostigmine methylsulfate daily dose without the dose-limiting gastrointestinal adverse effects associated with neostigmine methylsulfate.

Abstract: The present invention relates to compositions comprising an antiemetic, particularly including 5-HT3 antagonist and/or NK-1 antagonist antiemetics, in combination with a choline esterase inhibitor such as an acetylcholine esterase inhibitor and/or a butyrylcholine esterase inhibitor, and methods of using the composition to provide improved protection of subjects at risk of organophosphorus poisoning, or, for the treatment, prevention, or alleviation/reduction of toxicity from an organophosphorus compound, by enabling the use of a highly protective daily dose of the choline esterase inhibitor without the typical adverse effects.

Abstract: There is provided a convenient new treatment of Parkinson disease by a frequent administration of optimal levodopa doses mimicking a continuous intravenous or infusion treatment, thus mitigating motor complications; and a new carbidopa/levodopa pharmaceutical unit form providing said new treatment.

Abstract: The present invention describes the use of a NK1-antagonist, in constant combination with neostigmine, to facilitate the treatment of a patient suffering from myasthenia gravis by providing a therapeutically effective neostigmine bromide or methylsulfate daily dose without the dose-limiting gastrointestinal adverse effects.

Abstract: An assay for alpha synuclein and its various forms includes: a) providing a blood sample from a subject; b) isolating central nervous system (“CNS”) derived exosomes from the blood sample; c) removing proteins from the surface of the isolated exosomes to produce scrubbed exosomes; d) isolating the internal contents of the scrubbed exosomes; e) determining, in the isolated internal contents, a quantitative measure of oligomeric ?-synuclein protein and, optionally, one or a plurality of protein forms selected from: monomeric ?-synuclein, phosphorylated ?-synuclein, monomeric tau, oligomeric tau, phosphorylated tau, amyloid beta (“a-beta”) 1-40, amyloid beta 1-42, and oligomeric amyloid beta; f) separating species of oligomeric ?-synuclein into a plurality of fractions; g) determining a quantitative measure of each of one or a plurality of the separated oligomeric ?-synuclein species and, optionally, one or a plurality of species selected from: monomeric ?-synuclein, tau-synuclein co-polymers, amyloid beta-synuc

Abstract: The present invention describes the combination of a NK1-antagonist with pramipexole or a pharmaceutically acceptable salt or solvate thereof, useful for treating depressive disorders, including major depressive disorder.

Abstract: The present invention describes the combination of a NK1-antagonist with pramipexole or a pharmaceutically acceptable salt or solvate thereof, useful for treating depressive disorders, including major depressive disorder.

Abstract: The present invention describes the combination of a 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine or of a pharmaceutically acceptable salt or solvate thereof with fluoxetine or a pharmaceutically acceptable salt or solvate thereof, for use for treating a synucleinopathy such as Parkinson's disease, Lewy body disease, mutations in the glucocerebrosidase gene, or multiple system atrophy.

Abstract: The present invention describes the combination of domperidone with pramipexole or a pharmaceutically acceptable salt or solvate thereof, useful for treating depressive disorders, including major depressive disorder.

Abstract: The present invention describes the combination of a NK1-antagonist with pramipexole or a pharmaceutically acceptable salt or solvate thereof, useful for treating depressive disorders, including major depressive disorder.